These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8547241)

  • 21. Refined model for primer/template binding by HIV-1 reverse transcriptase: pre-steady-state kinetic analyses of primer/template binding and nucleotide incorporation events distinguish between different binding modes depending on the nature of the nucleic acid substrate.
    Wöhrl BM; Krebs R; Goody RS; Restle T
    J Mol Biol; 1999 Sep; 292(2):333-44. PubMed ID: 10493879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes.
    Proudfoot JR; Hargrave KD; Kapadia SR; Patel UR; Grozinger KG; McNeil DW; Cullen E; Cardozo M; Tong L; Kelly TA
    J Med Chem; 1995 Nov; 38(24):4830-8. PubMed ID: 7490732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase.
    Barnard J; Borkow G; Parniak MA
    Biochemistry; 1997 Jun; 36(25):7786-92. PubMed ID: 9201921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of nucleotide insertion and extension at 8-oxo-7,8-dihydroguanine by replicative T7 polymerase exo- and human immunodeficiency virus-1 reverse transcriptase using steady-state and pre-steady-state kinetics.
    Furge LL; Guengerich FP
    Biochemistry; 1997 May; 36(21):6475-87. PubMed ID: 9174365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
    Zhou Z; Madrid M; Evanseck JD; Madura JD
    J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site.
    Wu JC; Warren TC; Adams J; Proudfoot J; Skiles J; Raghavan P; Perry C; Potocki I; Farina PR; Grob PM
    Biochemistry; 1991 Feb; 30(8):2022-6. PubMed ID: 1705436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
    ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
    Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
    Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations.
    Basavapathruni A; Vingerhoets J; de Béthune MP; Chung R; Bailey CM; Kim J; Anderson KS
    Biochemistry; 2006 Jun; 45(23):7334-40. PubMed ID: 16752922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity.
    Campiani G; Nacci V; Fiorini I; De Filippis MP; Garofalo A; Greco G; Novellino E; Altamura S; Di Renzo L
    J Med Chem; 1996 Jul; 39(14):2672-80. PubMed ID: 8709096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1.
    Smerdon SJ; Jäger J; Wang J; Kohlstaedt LA; Chirino AJ; Friedman JM; Rice PA; Steitz TA
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3911-5. PubMed ID: 7513427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.
    Krebs R; Immendörfer U; Thrall SH; Wöhrl BM; Goody RS
    Biochemistry; 1997 Aug; 36(33):10292-300. PubMed ID: 9254628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative analysis of the endogenous reverse transcriptase reactions of HIV type 1 variants with decreased susceptibility to azidothymidine and nevirapine.
    Krogstad P; Chen IS; Canon J; Rey O
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):977-83. PubMed ID: 8827213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125.
    Udier-Blagović M; Tirado-Rives J; Jorgensen WL
    J Am Chem Soc; 2003 May; 125(20):6016-7. PubMed ID: 12785806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inactivation of human immunodeficiency virus type 1 reverse transcriptase by oltipraz: evidence for the formation of a stable adduct.
    Chavan SJ; Bornmann WG; Flexner C; Prochaska HJ
    Arch Biochem Biophys; 1995 Dec; 324(1):143-52. PubMed ID: 7503549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.
    Ren J; Nichols CE; Chamberlain PP; Weaver KL; Short SA; Stammers DK
    J Mol Biol; 2004 Feb; 336(3):569-78. PubMed ID: 15095972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorometric measurement of reverse transcriptase activity with 4',6-diamidino-2-phenylindole.
    Chavan SJ; Prochaska HJ
    Anal Biochem; 1995 Feb; 225(1):54-9. PubMed ID: 7539986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
    Auwerx J; Stevens M; Van Rompay AR; Bird LE; Ren J; De Clercq E; Oberg B; Stammers DK; Karlsson A; Balzarini J
    J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma.
    Vázquez-Rosales G; García Lerma JG; Yamamoto S; Switzer WM; Havlir D; Folks TM; Richman DD; Heneine W
    AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1191-200. PubMed ID: 10480632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Highly specific inhibitors of human immunodeficiency virus type I that are particularly targeted at the reverse transcriptase].
    de Clercq E; Snoeck R
    Pathol Biol (Paris); 1993 Mar; 41(3):230-6. PubMed ID: 7687340
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.